Accepted Manuscript

Accepted Manuscript (Uncorrected Proof)

Title: Artificial Intelligence in the Diagnosis and Treatment of Major Depression: A Multimodal, Model-Based Review

Authors: Fatemeh Abbasi[1], Niloufar Delfan[2], Fatemeh Zokayie[3], Mina Bayat Sefidi[4], Mahsa Ghanbarian[5], Arezou Ahmadi[6], Forugh Salajegheh[7], Mahdi Jafari Asl[8,*]

1. *Student Research Committee, Faculty of Medicine, Mazandaran University of Medical Sciences, Mazandaran, Iran.*
2. *Faculty of Computer Engineering, Dept. of Artificial Intelligence Engineering, K. N. Toosi University of Technology, Tehran, Iran.*
3. *Faculty of Medical science, Karaj Branch, Islamic Azad university, Karaj, Iran.*
4. *Department of Psychology, Faculty of Humanities, North Tehran Branch, Islamic Azad University, Tehran, Iran.*
5. *Department of Health Psychology, Faculty of Medical Sciences, Gorgan Branch, Islamic Azad University, Gorgan, Iran.*
6. *Department of Clinical Psychology, Faculty of Medical Sciences, Torbat-e jam Branch, Islamic Azad University, Torbat-e jam, Iran.*
7. *Department of Psychology, Ayatollah Amoli International Branch, Islamic Azad University, Amol, Mazandaran, Iran.*
8. *Department of Biomedical Engineering, Faculty of Engineering, Shahed University, Tehran, Iran.*

***Corresponding Author**: Mahdi Jafari Asl, Department of Biomedical Engineering, Faculty of Engineering, Shahed University, Tehran, Iran. Email: mahdi.jafariasl@shahed.ac.ir

To appear in: **Basic and Clinical Neuroscience**

Received date: 2025/08/10

Revised date: 2025/12/25

Accepted date: 2025/12/30

Please cite this article as:

Abbasi, F., Delfan, N., Zokayie, F., Bayat Sefidi, M., Ghanbarian, M., Ahmadi, A., et al. (In Press). Artificial Intelligence in the Diagnosis and Treatment of Major Depression: A Multimodal, Model-Based Review. Basic and Clinical Neuroscience. Just Accepted publication Jul. 10, 2026. Doi: http://dx.doi.org/10.32598/bcn.2026.7612.3

DOI: http://dx.doi.org/10.32598/bcn.2026.7612.3

Abstract

Background: Depression is a widespread and multifaceted mental health disorder that profoundly affects quality of life and productivity. It is characterized by persistent sadness, loss of interest, and various physical and cognitive symptoms. Traditional diagnostic approaches often rely on subjective assessments, resulting in delayed or inaccurate diagnoses, and typically lack personalization in treatment planning.

Objective: This study investigates recent advancements in artificial intelligence (AI) for the diagnosis, treatment, and monitoring of depression. The integration of deep learning (DL) algorithms with multimodal data sources, including genetic, behavioral, neuroimaging, and digital signals, offers new opportunities to enhance clinical decision-making and develop more precise, individualized interventions.

Methods: A comprehensive literature review was conducted focusing on AI-driven techniques, including machine learning (ML), deep learning, and natural language processing (NLP). These were applied to multimodal datasets such as neuroimaging (e.g., EEG, fMRI, fNIRS), genetic profiles, wearable sensor data (e.g., heart rate, sleep patterns), and behavioral indicators (e.g., voice, facial expressions, social media use). AI architectures examined include CNNs, Recurrent Neural Networks (RNNs), LSTMs, and Transformer-based models.

Results: AI has demonstrated high accuracy (85–90%) in detecting depressive states and predicting treatment outcomes. Wearable-AI systems enable continuous mood monitoring and early relapse detection, while deep learning models outperform traditional diagnostic tools across various datasets.

Conclusion: AI is redefining depression care by supporting scalable, timely, and personalized solutions. However, challenges remain, including model interpretability, data privacy, and clinical validation. Future work must focus on ethically designed, explainable, and robust AI systems to ensure safe deployment in clinical practice.

Keywords: Artificial Intelligence, Major Depressive Disorder, Machine Learning, Clinical Decision Support, Mental Health Technology, Deep Learning, Precision Psychiatry

1 Introduction

Depression is a pervasive and multifactorial mental disorder, affecting over 280 million individuals globally, and is a leading contributor to disability and suicide. Despite its high prevalence, depression remains underdiagnosed and undertreated, often due to the limitations of conventional diagnostic approaches that rely heavily on subjective clinical assessments and self-reported symptoms. Early diagnosis and timely intervention are essential to improve patient outcomes and prevent long-term functional impairment.

In recent years, artificial intelligence (AI) has emerged as a transformative tool in the realm of mental health, enabling the development of data-driven systems for more accurate, efficient, and personalized care. AI refers to the capability of machines and computer systems to emulate human cognitive processes, such as learning, reasoning, problem-solving, and perception, through a variety of techniques, including machine learning (ML), deep learning (DL), natural language processing (NLP), and computer vision. For clarity and consistency, the term “AI” is used throughout this manuscript as an umbrella concept encompassing ML, DL, and related computational approaches. The expression “AI-based systems” refers to clinical or research platforms that incorporate AI algorithms for diagnostic, predictive, or therapeutic purposes. Alternative terms such as “AI-driven tools” or “intelligent systems” are avoided to maintain terminological consistency.

The integration of AI in psychiatry has been accelerated by the widespread availability of multimodal datasets and the rapid evolution of computational power. AI-based systems are now being used to detect depressive symptoms through various techniques, including neuroimaging methods (e.g., Functional Magnetic Resonance Imaging (fMRI), Electroencephalogram (EEG), and Functional Near-Infrared Spectroscopy (fNIRS), behavioral analysis (e.g., speech, facial expressions, and movement patterns), and biosignal monitoring via wearable sensors. These technologies offer continuous, objective, and non-invasive monitoring of key biomarkers, such as heart rate variability, sleep quality, oxygen saturation, and physical activity, often altered in individuals with depression. ML algorithms, such as Support Vector Machines (SVM), Random Forests (RF), Convolutional Neural Networks (CNN), and Long Short-Term Memory Networks (LSTM), have been successfully employed to classify depression severity, predict treatment outcomes, and identify individuals at high risk. For example, some studies [80-82] demonstrated that ML models trained on multimodal data, encompassing genetic, neurobiological, and clinical features, can accurately predict disease trajectory and response to antidepressant therapies. The advent of wearable AI, integrating wearable devices and intelligent algorithms, has opened new frontiers in passive and real-time mental health monitoring. Studies utilizing datasets such as the depression dataset and PHQ-9-based assessments have shown promising results in identifying depressive episodes with high accuracy. Moreover, AI has the potential to revolutionize personalized medicine in psychiatry by analyzing large-scale datasets to tailor treatment regimens based on individual profiles, including genetic predisposition, comorbid conditions, treatment history, and behavioral responses. These developments align with the goals of precision psychiatry, which seeks to move beyond the “one-size-fits-all” approach toward targeted and adaptive interventions. Despite these advancements, several challenges remain. Issues related to data privacy, algorithm transparency, clinical interpretability, and ethical use of AI in psychiatry must be carefully addressed. Nevertheless, the ongoing convergence of AI, neuroscience, and wearable technologies signals a promising future for AI-enabled mental health care. This review aims to critically evaluate the current applications, challenges, and future directions of AI-based approaches in diagnosing and treating major depressive disorder.

2 Depression

Emotional, cognitive, and physical functioning. Despite its prevalence, nearly 60% of individuals suffering from depression do not seek medical help, primarily due to societal stigma and misconceptions surrounding mental health. This social barrier not only impedes timely intervention but also exacerbates the individual's emotional distress and functional decline [24]. Clinically, depression is characterized by persistent sadness, loss of interest or pleasure, low energy, poor sleep and appetite, difficulty concentrating, and suicidal ideation [25, 30, 31]. According to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), depressive disorders are classified into several categories. These include Major Depressive Disorder (MDD), Persistent Depressive Disorder (PDD: Dysthymia), Disruptive Mood Dysregulation Disorder (DMDD), Premenstrual Dysphoric Disorder (PDD), and Depressive Disorder (DD) due to other medical conditions [26]. Each of these categories represents distinct patterns of depressive symptoms, onset, and duration, which are crucial for accurate diagnosis and appropriate treatment planning.

MDD alone affects approximately 5–17% of the population during their lifetime [27], leading to substantial functional disability, interpersonal difficulties [28], and a significant reduction in quality of life [29]. In severe cases, depression may evolve into chronic conditions and can even lead to suicidal behaviors, contributing to an alarming global public health concern [31,35]. According to the World Health Organization (WHO), over 300 million people suffer from depression globally, with approximately 800,000 annual deaths due to suicide. Depression accounts for 7.5% of global years lived with disability (YLD), making it the leading cause of non-fatal health burden worldwide [36].

Despite its severity, depression lacks a definitive diagnostic laboratory test. Diagnosis is typically based on clinical interviews, patient history, and the evaluation of symptoms, while laboratory tests are primarily used to exclude other potential medical conditions [32–34]. The etiology of depression is multifactorial, involving a complex interplay of biological and genetic factors [37], psychosocial stressors such as trauma, bereavement, social isolation, financial difficulties, or interpersonal conflict [39], and neuromodulatory dysregulation, as indicated by recent research findings [38]. Treatment of depression includes pharmacological interventions (e.g., antidepressants) and psychotherapeutic approaches such as Cognitive Behavioral Therapy (CBT) and Interpersonal Therapy (IPT). Studies demonstrate that combined therapy often yields superior outcomes in symptom relief and relapse prevention compared to monotherapy alone [40, 41].

Moreover, patient and family education is crucial for treatment adherence and outcome optimization. Misconceptions framing depression as personal weakness foster stigma, discouraging diagnosis and intervention. By improving public awareness, promoting education, and facilitating access to care, early diagnosis and effective treatment of depression can be significantly enhanced.

3 Search Strategy and Inclusion Criteria

This study was conducted as a narrative review aimed at providing a comprehensive and integrative overview of artificial intelligence applications in the diagnosis, monitoring, and treatment of major depressive disorder. A narrative review approach was selected due to the conceptual diversity, methodological heterogeneity, and rapid evolution of AI-based techniques, which limit the feasibility of applying a rigid systematic review framework.

The literature search was performed using PubMed, Scopus, and Web of Science databases. Articles published between 2015 and 2024 were considered. The search strategy included combinations of keywords such as "artificial intelligence," "machine learning (ML)," "deep learning (DL)," "major depressive disorder," "depression," "mental health," "wearable technology," "neuroimaging," "EEG," "natural language processing," and "clinical decision support systems."

Inclusion criteria comprised peer-reviewed studies that investigated AI-driven diagnostic, predictive, monitoring, or therapeutic applications related to depression in clinical or translational settings. Exclusion criteria included non-English publications, studies focusing exclusively on non-clinical AI theory, editorials without empirical or conceptual contribution, and studies unrelated to depressive disorders.

Study selection was conducted through title and abstract screening, followed by full-text review to assess relevance. Due to the narrative nature of the review, studies were selected based on conceptual relevance and contribution to the understanding of AI-based approaches in depression rather than quantitative aggregation.

4 AI Data Modalities for Depression

Artificial intelligence (AI) has profoundly transformed neuroscience and mental healthcare by enabling the processing of complex medical and behavioral datasets to identify patterns that support diagnosis, treatment planning, and prognosis. In the context of depression, AI technologies are increasingly applied to enhance detection, predict outcomes, and personalize interventions [42, 48].

Recent studies have demonstrated the utility of ML and AI-powered systems in mental health. Techniques such as audiovisual analysis and EEG-based classification have been successfully employed to identify depressive symptoms [3, 49]. Clinical Decision Support Systems (CDSS), such as Aifred, have shown promise in aiding physicians with treatment planning for MDD, improving communication and trust between patients and healthcare providers [50-52]. Furthermore, AI models have been used to simulate psychiatric symptom progression, optimize pharmacological interventions, and provide real-time monitoring with personalized recommendations [54].

ML algorithms have also demonstrated predictive capabilities for treatment outcomes in MDD. Meta-analyses and real-world studies emphasize the integration of diverse predictors, including physiological, behavioral, and cognitive markers, to improve individualized care [55-56].

These approaches highlight the growing role of AI in personalized mental healthcare and long-term monitoring.

AI-based approaches to depression leverage multiple data modalities that capture complementary aspects of emotional, cognitive, and behavioral functioning. These modalities can be broadly categorized into four main groups: neurobiological, behavioral, physiological, and digital.

Neurobiological modalities include EEG, fMRI, and fNIRS. EEG provides high temporal resolution and cost-effective real-time monitoring, but is sensitive to noise and often limited by small sample sizes. fMRI offers high spatial resolution and enables network-level analyses, but is expensive, less accessible, and less feasible for routine clinical use. fNIRS represents a portable alternative for measuring cortical activity, though with lower spatial resolution than fMRI.

Behavioral and physiological modalities encompass heart rate variability, sleep patterns, physical activity, and circadian rhythms, typically collected via wearable devices and smartphone sensors. These sources enable continuous, ecologically valid monitoring of depressive symptoms, supporting longitudinal tracking, population-level screening, and relapse detection. Although predictive accuracy is moderate, their scalability and real-world applicability make them valuable tools for mental health monitoring.

Digital modalities include speech, text, and NLP analyses. Acoustic features, linguistic patterns, and semantic content from clinical interviews, social media, or digital interactions can indicate affective and cognitive changes associated with depression. Despite their potential, these approaches require careful consideration of privacy, cultural bias, and cross-linguistic generalizability.

Overall, multimodal data integration consistently outperforms unimodal approaches by capturing complementary information across domains. However, increasing modality diversity introduces challenges in data harmonization, computational complexity, and interpretability, emphasizing the importance of balanced and clinically informed model design.

5 AI Models and Architectures

AI has emerged as a transformative tool in psychology, providing novel approaches for understanding, diagnosing, and treating mental health disorders. By leveraging diverse datasets, including behavioral patterns, speech characteristics, and digital footprints such as social media activity, AI models can identify subtle indicators and risk factors associated with psychological conditions [62-63].

Recent advances highlight the role of AI-powered virtual agents, such as chatbots and virtual therapists, in delivering real-time mental health support and counseling. ML algorithms have been employed to detect early signs of depression from social media content, achieving notable predictive accuracy [1,60–62]. Similarly, AI-driven interventions can personalize support, monitor progress, and reduce symptoms of anxiety and depression. Beyond direct patient care, AI also enhances clinical decision-making by processing patient data to assist mental health professionals, while scholars emphasize the importance of integrating AI competencies into psychology curricula to prepare future practitioners [64-66].

A wide range of AI models has been applied to depression-related tasks, spanning classical ML methods and advanced DL architectures. The choice of model is influenced by data modality, sample size, and intended clinical application.

Classical ML models, including SVM, RF, and Logistic Regression (LR), remain widely used due to their simplicity, robustness to small datasets, and interpretability. These models are particularly effective with structured clinical, behavioral, or physiological features, offering transparent decision boundaries that foster clinical trust. However, they often underperform with high-dimensional or raw data, such as neuroimaging signals or speech waveforms.

DL architectures, including CNNs and LSTM networks, excel in processing complex and unstructured data. CNNs are effective for spatial feature extraction in EEG and imaging datasets, whereas LSTMs capture temporal dependencies in speech, text, and longitudinal sensor data. Transformer-based models, increasingly applied in natural language processing tasks, leverage attention mechanisms to model long-range semantic relationships in clinical interviews and digital text. Despite their superior performance, DL models face challenges related to explainability, computational cost, and overfitting, particularly with small or homogeneous datasets.

Multimodal fusion models integrate heterogeneous data sources, behavioral, physiological, and neurobiological, to enhance predictive performance. While these models capture complementary information across domains, they increase complexity and reduce interpretability, requiring careful design, validation, and clinical oversight.

No single architecture is universally optimal for depression-related applications. Model selection must balance accuracy, interpretability, data availability, and clinical feasibility. A model-aware, context-sensitive approach is essential for leveraging AI effectively in precision psychiatry, guiding personalized interventions and informed clinical decision-making.

6 Diagnostic Applications of AI in Major Depression

AI is increasingly transforming healthcare by enhancing diagnostic accuracy and supporting evidence-based therapeutic decisions. Leveraging advanced data processing capabilities, AI algorithms can systematically analyze diverse datasets, including imaging, laboratory tests, electronic health records, and behavioral data, to assist clinicians in timely and precise decision-making [67, 68].

AI has demonstrated utility across various medical domains. In dermatology, DL models classified skin cancer with performance comparable to board-certified dermatologists [67]. In ophthalmology, AI-based systems detected diabetic retinopathy from retinal fundus images with high sensitivity and specificity, enabling earlier intervention [68]. Beyond common conditions, AI has streamlined complex diagnostic workflows and facilitated individualized pharmacological regimens, highlighting its potential in rare disease management [69, 70]. In mental health, AI-powered clinical decision support systems have shown promise in early detection and treatment planning for psychiatric disorders [71,72]. Collectively, these advances illustrate AI's transformative potential in precision medicine.

Specifically for MDD, AI-based diagnostic applications aim to improve early detection, classification, and risk stratification. By integrating multimodal patient data, AI models can uncover latent patterns not readily identifiable through conventional clinical assessment. Speech analytics, smartphone sensor data, and neuroimaging-based classifiers have demonstrated promising performance in differentiating depressed individuals from healthy controls, estimating symptom severity, and predicting disease onset. Multimodal systems that combine behavioral and physiological data generally outperform single-modality approaches, providing more robust and ecologically valid predictions.

Despite these advancements, diagnostic accuracy varies across studies due to differences in dataset size, feature extraction techniques, and validation strategies. Many models rely on retrospective or cross-sectional datasets and lack external validation, limiting generalizability. Furthermore, the heterogeneous presentation of depressive symptoms complicates the development of universally applicable diagnostic models. AI-driven diagnostic tools should be regarded as complementary aids rather than replacements for clinician judgment. Ensuring robust validation, transparency, and seamless integration within clinical workflows is essential for the safe and effective deployment of AI in depression diagnostics.

7 AI-Based Treatment and Monitoring Approaches

AI has shown considerable promise in enhancing the treatment and monitoring of MDD, a condition often characterized by heterogeneous presentations and diagnostic complexity. By integrating data from clinical interviews, electronic health records, genetic profiles, and behavioral sensors, AI algorithms can identify latent patterns indicative of depressive states, enabling early detection and personalized intervention.

Empirical studies have demonstrated the feasibility of AI in treatment and monitoring. Saeb et al. (2015) [76] utilized passive smartphone sensor data to predict depressive episodes with significant accuracy, while Cummins et al. (2021) applied audio and text sequence modeling of clinical interviews to differentiate depressed individuals from healthy controls [76]. These findings underscore the potential of multimodal data, from speech signals to mobility patterns, in constructing reliable diagnostic and monitoring models.

AI-driven platforms, including NLP systems and conversational agents, facilitate continuous mental health support. These tools offer accessible, stigma-free interventions, particularly for individuals with limited access to traditional mental health services [73, 74]. By tracking behavioral and physiological markers, AI systems provide personalized feedback, contribute to digital psychotherapy, and support longitudinal care [80, 81].

CDSS represent one of the most mature applications of AI in MDD treatment. These platforms integrate clinical, demographic, and treatment history data to inform personalized therapy recommendations, enhance shared decision-making, and optimize treatment planning. AI-assisted treatment tools have shown clinician acceptance and feasibility, particularly in tailoring interventions to individual patient profiles.

Digital therapeutics, including AI-powered mobile applications and conversational agents, deliver scalable interventions for symptom management. Controlled and observational studies report reductions in depressive symptoms, especially in mild to moderate cases. Additionally, wearable AI systems enable continuous monitoring of mood-related behavioral and physiological markers, supporting early relapse detection and real-time care adjustments.

Despite these advancements, most AI-based treatment tools remain in pilot or research stages. Evidence from large-scale randomized controlled trials is limited, and real-world effectiveness may be affected by user engagement, adherence, and ethical considerations. Therefore, AI-assisted treatment approaches should be implemented cautiously, with rigorous evaluation and integration within clinical workflows.

8 Clinical Translation and Implementation Challenges

The integration of AI into the treatment of MDD represents a transformative paradigm in mental healthcare. AI-based systems not only support diagnosis but also enhance therapeutic outcomes through personalized and adaptive interventions. By analyzing diverse data modalities, including audio-visual inputs (speech, facial expressions), neuroimaging, and physiological signals, AI models can detect and classify depressive symptom severity with high accuracy, providing clinicians with comprehensive, data-driven insights for timely decision-making [3, 49].

One notable example is the AI-powered clinical decision support system Aifred, which has demonstrated feasibility, clinician acceptance, and improved shared decision-making by increasing patient understanding and trust in therapeutic recommendations [51]. Wearable AI technologies further support real-time monitoring and prescreening of depressive and anxiety symptoms, particularly in outpatient and community-based settings [81].

Beyond clinical environments, psychological AI platforms offer population-specific interventions. For instance, Tess, an integrative conversational agent, has been linked to significant reductions in depressive and anxiety symptoms among college students, providing scalable, responsive support [82]. Mobile applications such as Youper offer cost-effective, self-guided approaches to mental health management, leveraging emotion regulation tracking and reinforcement strategies to reduce symptom severity. These tools enhance accessibility and empower users to actively manage their emotional well-being.

ML algorithms also enable the identification of latent biomarkers through structural imaging, EEG patterns, and genetic profiling. Such approaches facilitate patient stratification and treatment response prediction, paving the way for precision psychiatry [3, 8, 83]. Compared to traditional interventions, AI-assisted therapies have shown superior outcomes in symptom reduction and patient retention, highlighting their potential to augment standard care and address gaps in mental health service delivery.

Despite these advances, clinical translation faces several challenges. A major limitation is the restricted generalizability of AI models due to small, homogeneous datasets and limited external validation. Algorithmic transparency and explainability are crucial for clinician trust and regulatory approval; black-box models, while accurate, complicate clinical interpretation and accountability. Data privacy, security, and bias are additional concerns, especially when sensitive behavioral or digital data are used.

Integration into existing clinical workflows is another critical challenge. AI tools must align with clinician decision-making, minimize additional burden, and demonstrate clear added value. Successful deployment requires multidisciplinary collaboration among clinicians, data scientists, ethicists, and policymakers to ensure responsible design and implementation.

Addressing these clinical, technical, and ethical challenges through rigorous validation, ethical design, and regulatory oversight is essential to realize the full potential of AI in depression care, ensuring safe, effective, and sustainable integration into mental health systems.

9 Discussion

From a critical perspective, the performance of AI models in depression research varies substantially as a function of data modality, model architecture, and validation strategy. Multimodal approaches that integrate behavioral, physiological, and neuroimaging data consistently outperform unimodal systems by capturing complementary dimensions of depressive symptomatology. However, these performance gains are frequently accompanied by increased model complexity, reduced interpretability, and higher data acquisition and processing burdens, which may limit clinical scalability.

Neuroimaging-based models, particularly those employing EEG and fMRI data in conjunction with DL architectures, often report higher classification accuracies compared to other modalities. Nevertheless, such models are commonly trained on relatively small and homogeneous datasets and frequently lack external or prospective validation, thereby constraining their clinical generalizability. In contrast, wearable- and smartphone-based systems typically achieve moderate predictive accuracy but offer significant advantages in terms of scalability, longitudinal monitoring, ecological validity, and feasibility in real-world clinical and community settings.

A recurrent trade-off observed across studies is the balance between predictive accuracy and model explainability. DL models, including CNNs, LSTMs, and transformer-based architectures such as Bidirectional Encoder Representations from Transformers (BERT), generally outperform classical ML methods in complex classification and pattern recognition tasks. However, their inherent "black-box" nature presents challenges for clinical interpretability, accountability, and clinician trust. Conversely, classical ML models, such as

SVM and RF, offer greater transparency and interpretability but may underperform when applied to high-dimensional, unstructured, or multimodal datasets.

Importantly, many of the reported accuracy values in the literature (e.g., 82–90%) are derived from experimental, retrospective, or proof-of-concept studies and should not be interpreted as indicators of immediate clinical readiness. Robust and clinically meaningful findings are typically supported by multi-site datasets, longitudinal designs, repeated cross-validation, or external validation cohorts. In contrast, exploratory studies often rely on limited sample sizes and single-cohort evaluations, underscoring the need for caution when extrapolating experimental performance metrics to real-world clinical practice.

The inclusion of AI in the diagnosis and treatment of major depressive disorder represents a paradigm shift in mental healthcare. As summarized in Table 1, a wide range of AI techniques, including ML algorithms, natural language processing methods, wearable sensing technologies, and digital therapeutics, have been employed to enhance diagnostic accuracy, personalize treatment protocols, and extend access to care. The reviewed

Table 1: A Comparative overview of representative AI-based studies in the diagnosis and treatment of major depressive disorder

Study/Author	Modality Used	AI Model	Target	Accuracy (%)
Saeb et al., 2015	Smartphone Sensors	RF	Predicting depressive mood	77%
Cummins et al., 2021	Audio/Text	LSTM, BERT	Diagnosing MDD	84%
Aifred (Benrimoh, 2021)	Clinical Data	CDSS (ML)	Treatment Selection	85%
Shah et al., 2022	Wearables	Personalized ML	Mood tracking	80%
Representative multimodal AI studies	EEG, NLP, Neuroimaging	CNN-LSTM	Diagnosis and Longitudinal Monitoring*	82–90%

*Reported accuracy ranges reflect experimental performance across heterogeneous datasets and study designs. Direct comparison across studies should be interpreted with caution due to differences in sample size, validation strategies, and data modalities.

Studies utilize diverse data modalities, ranging from smartphone sensor data and wearable devices to audio–text analysis and structured clinical datasets. Correspondingly, a variety of models, such as Random Forest, LSTM, BERT, and CNN architectures, have been applied to tasks including mood prediction, MDD diagnosis, symptom severity estimation, and personalized treatment selection. While reported performance varies depending on data type and methodological complexity, DL approaches generally achieve superior accuracy within multimodal frameworks. Notably, CNN–LSTM–based architectures in recent studies have reported accuracies ranging from 82% to 90%, highlighting the potential of AI-assisted approaches in depression care.

Beyond diagnostic performance, AI technologies have demonstrated strong capability in detecting depressive symptoms from diverse information sources, including speech characteristics, facial expressions, social media activity, and passive smartphone or wearable sensor data. These approaches enable early identification of at-risk individuals, often prior to overt clinical manifestation, thereby facilitating timely intervention and preventive care.

Empirical studies using voice analysis and sensor-derived behavioral features have shown promising results in distinguishing depressed from non-depressed individuals with high accuracy.

With respect to treatment, AI-guided interventions, such as virtual therapists, mobile mental health applications, and clinical decision support systems, have shown efficacy in reducing depressive symptoms and improving patient outcomes. These tools not only expand access to mental health services but also support clinicians in evidence-based, data-driven decision-making, thereby enhancing the quality, consistency, and effectiveness of care delivery.

Figure 1 illustrates a conceptual pipeline for integrating AI into the diagnosis, monitoring, and treatment of MDD. The pipeline begins with the acquisition of heterogeneous patient data, including multimodal inputs such as speech patterns, wearable sensor outputs, neuroimaging data (EEG, fMRI), genetic profiles, and behavioral indicators (e.g., social media activity and physical movement). These data streams are processed through advanced ML and DL algorithms, including SVM, CNN, LSTM, and transformer-based models such as BERT, to extract meaningful features and latent patterns. The resulting outputs support multiple clinical applications, including early and accurate diagnosis, real-time symptom monitoring, personalized treatment planning, and relapse risk prediction. This framework highlights AI's capacity to synthesize high-dimensional, heterogeneous data and complement traditional clinical assessment, advancing the field toward precision psychiatry.



Figure 1 Conceptual framework illustrating the integration of artificial intelligence into the diagnosis, monitoring, and treatment of major depressive disorder. This figure represents a conceptual overview rather than an empirical or validated system [AI-based].

In addition, AI applications in neuroimaging, genomics, and EEG analysis facilitate the identification of potential biomarkers for depression, contributing to more objective diagnostic and prognostic assessments. By enabling the analysis of large-scale, multidimensional datasets, AI supports the development of personalized and adaptive treatment strategies that move beyond conventional "one-size-fits-all" approaches.

Despite these promising advancements, several challenges remain. Issues related to data privacy, ethical considerations, algorithmic bias, and insufficient clinical validation, particularly in multicultural and diverse populations, must be systematically addressed. Robust regulatory frameworks are required to ensure the safe and ethical deployment of AI in mental health settings. Furthermore, clinician and patient acceptance, alongside seamless integration into existing clinical workflows, are essential for sustainable implementation.

In summary, while AI holds substantial potential to transform the diagnosis and treatment of major depression, its successful integration into clinical psychiatry depends on multidisciplinary collaboration among AI developers, clinicians, researchers, and policymakers. Future research should prioritize longitudinal studies, cross-cultural validation, explainable AI models, and large-scale, multi-center clinical trials. Crucially, a clear distinction must be maintained between research-stage AI systems and clinically validated tools, as high experimental performance does not necessarily translate into real-world clinical effectiveness.

9 Conclusion

The integration of artificial intelligence (AI) into the diagnosis and treatment of major depressive disorder (MDD) represents a transformative advancement in contemporary mental healthcare. By leveraging machine learning (ML) algorithms, wearable technologies, and neuroimaging modalities, AI has improved diagnostic precision, enabled predictive modeling, and facilitated the development of personalized therapeutic strategies. These innovations provide scalable and cost-effective alternatives to traditional approaches, addressing both clinical and systemic gaps in mental health service delivery.

Nevertheless, the widespread adoption of AI in psychiatry requires careful attention to critical challenges, including data privacy, algorithmic transparency, ethical considerations, and the need for robust clinical validation. Ensuring responsible and equitable deployment is essential for maintaining patient trust and safeguarding clinical integrity. Moreover, most current AI-based solutions remain in research or pilot stages, and reported accuracy metrics largely reflect experimental performance rather than real-world clinical effectiveness.

Looking forward, sustained interdisciplinary collaboration among AI researchers, clinicians, and policymakers will be crucial for refining AI-driven interventions and translating technological advancements into tangible health benefits. Large-scale, multi-center validation studies, regulatory oversight, and seamless integration into clinical workflows are necessary to realize AI's full potential in routine psychiatric practice.

By prioritizing ethical design, clinical efficacy, and accessibility, AI holds significant promise to transform depression care, enhance mental health outcomes, and reduce the global burden of depression. However, its impact will depend on the responsible alignment of technological innovation with clinical and societal needs.

References

1. Eid MM, Yundong W, Mensah GB, Pudasaini P. Treating Psychological Depression Utilising Artificial Intelligence: AI for Precision Medicine- Focus on Procedures. Mesopotamian Journal of Artificial Intelligence in Healthcare. 2023;2023:76-81.
2. Aziz S, Alsaad R, Abd-Alrazaq A, Ahmed A, Sheikh J. Performance of artificial intelligence in predicting future depression levels. Studies in health technology and informatics. 2023;305:452-5.
3. Tran BX, McIntyre RS, Latkin CA, Phan HT, Vu GT, Nguyen HLT, et al. The current research landscape on the artificial intelligence application in the management of depressive disorders: a bibliometric analysis. International journal of environmental research and public health. 2019;16(12):2150.
4. Kaplan A, Haenlein M. Siri, Siri, in my hand: Who's the fairest in the land? On the interpretations, illustrations, and implications of artificial intelligence. Business horizons. 2019;62(1):15-25.
5. Ledley R, Lusted L. Reasoning foundations of medical diagnosis. MD computing: computers in medical practice. 1991;8(5):300-15.
6. Gao S, Calhoun VD, Sui J. Machine learning in major depression: From classification to treatment outcome prediction. CNS neuroscience & therapeutics. 2018;24(11):1037-52.
7. Laksshman S, Bhat RR, Viswanath V, Li X. DeepBipolar: Identifying genomic mutations for bipolar disorder via deep learning. Hum Mutat. 2017;38(9):1217-24.
8. Dopico M, Gómez A, De la Fuente D, García N, Rosillo R, Puche J, editores. A vision of Industry 4.0 from an artificial intelligence point of view. Proceedings of the international conference on artificial intelligence (ICAI); 2016: The Steering Committee of The World Congress in Computer Science, Computer.
9. de Kleijn M, Siebert M, Huggett S. Artificial Intelligence: How knowledge is created, transferred and used. 2017.
10. Patel MJ, Khalaf A, Aizenstein HJ. Studying depression using imaging and machine learning methods. NeuroImage: Clinical. 2016;10:115-23.
11. Dinga R, Marquand AF, Veltman DJ, Beekman AT, Schoevers RA, van Hemert AM, et al. Predicting the naturalistic course of depression from a wide range of clinical, psychological, and biological data: a machine learning approach. Translational psychiatry. 2018;8(1):241.
12. Garcia-Ceja E, Riegler M, Jakobsen P, Tørresen J, Nordgreen T, Oedegaard KJ, et al., editors. Depresjon: a motor activity database of depression episodes in unipolar and bipolar patients. Proceedings of the 9th ACM multimedia systems conference; 2018.
13. Choi J, Lee S, Kim S, Kim D, Kim H. Depressed mood prediction of elderly people with a wearable band. Sensors. 2022;22(11):4174.
14. Dai R, Kannampallil T, Zhang J, Lv N, Ma J, Lu C. Multi-task learning for randomized controlled trials: a case study on predicting depression with wearable data. Proceedings of the ACM on Interactive, Mobile, Wearable and Ubiquitous Technologies. 2022;6(2):1-23.
15. Espino-Salinas CH, Galván-Tejada CE, Luna-García H, Gamboa-Rosales H, Celaya-Padilla JM, Zanella-Calzada LA, et al. Two-dimensional convolutional neural network for depression episode detection in real time using motor activity time series of the depression

dataset. Bioengineering. 2022;9(9):458.
16. Frogner JI, Noori FM, Halvorsen P, Hicks SA, Garcia-Ceja E, Torresen J, et al., editors. One-dimensional convolutional neural networks on motor activity measurements in the detection of depression. Proceedings of the 4th International Workshop on Multimedia for Personal Health & Health Care; 2019.
17. Galvan-Tejada CE, Zanella-Calzada LA, Gamboa-Rosales H, Galván-Tejada JI, Chávez-Lamas NM, Gracia-Cortés M, et al. Depression episodes detection in unipolar and bipolar patients: a methodology with feature extraction and feature selection with genetic algorithms using the activity motion signal as information source. Mobile Information Systems. 2019;2019.
18. Mullick T, Radovic A, Shaaban S, Doryab A. Predicting depression in adolescents using mobile and wearable sensors: multimodal machine learning–based exploratory study. JMIR Formative Research. 2022;6(6):e35807.
19. Lee EE, Torous J, De Choudhury M, Depp CA, Graham SA, Kim H-C, et al. Artificial intelligence for mental health care: clinical applications, barriers, facilitators, and artificial wisdom. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging. 2021;6(9):856-64.
20. Oğur NB, Çeken C, Oğur YS, Yuvaci HU, Yazici AB, Yazici E. Development of an artificial intelligence-supported hybrid data management platform for monitoring depression and anxiety symptoms in the perinatal period: Pilot-scale study. IEEE Access. 2023;11:31456-66.
21. Rubeis G. iHealth: The ethics of artificial intelligence and big data in mental healthcare. Internet Interventions. 2022;28:100518.
22. Rosenfeld A, Benrimoh D, Armstrong C, Mirchi N, Langlois-Therrien T, Rollins C, et al. Big Data analytics and artificial intelligence in mental healthcare. Applications of big data in healthcare: Elsevier; 2021. p. 137-71.
23. Orlu GU, Abdullah RB, Zaremohzzabieh Z, Jusoh YY, Asadi S, Qasem YA, et al. A systematic review of literature on sustaining decision-making in healthcare organizations amid imperfect information in the Big Data era. Sustainability. 2023;15(21):15476.
24. Sanmukhani J, Satodia V, Trivedi J, Patel T, Tiwari D, Panchal B, et al. Efficacy and safety of curcumin in major depressive disorder: a randomized controlled trial. Phytotherapy research. 2014;28(4):579-85.
25. Hsu H, Siwiec R. StatPearls Publishing. Treasure Island, FL. 2022.
26. Ormel J, Kessler RC, Schoevers R. Depression: More treatment but no drop in prevalence: how effective is treatment? And can we do better? Current opinion in psychiatry. 2019;32(4):348-
27. Kessler RC, Bromet EJ. The epidemiology of depression across cultures. Annual review of public health. 2013;34:119-38.
28. Almeida SS, Zizzi FB, Cattaneo A, Comandini A, Di Dato G, Lubrano E, et al. Management and treatment of patients with major depressive disorder and chronic diseases: a multidisciplinary approach. Frontiers in psychology. 2020;11:542444.
29. Ghahremani A, Mosa Farkhani S, Baniasadi M, Hojjat SK, Namdar Ahmadabad H, Salarbashi D, et al. Personality traits of patients with multiple sclerosis and their correlation with anxiety and depression levels: A cross-sectional case–control study. Brain and Behavior. 2022;12(5):e2596.

30. Puri BK, Hall AD, Ho R. Revision notes in psychiatry: Arnold London; 2004.
31. Marcus M, Yasamy MT, van Ommeren Mv, Chisholm D, Saxena S. Depression: A global public health concern. 2012.
32. Mangla K, Hoffman MC, Trumpff C, O'Grady S, Monk C. Maternal self-harm deaths: an unrecognized and preventable outcome. American journal of obstetrics and gynecology. 2019;221(4):295-303.
33. Shelton RC. Serotonin and norepinephrine reuptake inhibitors. Antidepressants: From Biogenic Amines to New Mechanisms of Action. 2019:145-80.
34. Tanner J, Zeffiro T, Rufer M, Mueller-Pfeiffer C. Psychiatric symptom profiles predict functional impairment. Frontiers in psychiatry. 2019;10:409682.
35. Lim GY, Tam WW, Lu Y, Ho CS, Zhang MW, Ho RC. Prevalence of depression in the community from 30 countries between 1994 and 2014. Scientific reports. 2018;8(1):2861.
36. Depression W. Other common mental disorders: global health estimates. Geneva: World Health Organization. 2017;24.
37. Kendall K, Van Assche E, Andlauer T, Choi K, Luykx J, Schulte E, et al. The genetic basis of major depression. Psychological Medicine. 2021;51(13):2217-30.
38. Li Z, Ruan M, Chen J, Fang Y. Major depressive disorder: advances in neuroscience research and translational applications. Neuroscience bulletin. 2021;37:863-80.
39. Chand SP, Arif H, Kutlenios RM. Depression (nursing). 2021.
40. Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms. The Lancet Psychiatry. 2019;6(6):538-46.
41. Knappe S, Einsle F, Rummel-Kluge C, Heinz I, Wieder G, Venz J, et al. Simple guideline-oriented supportive tools in primary care: Effects on adherence to the S3/NV guideline for unipolar depression. Zeitschrift für Psychosomatische Medizin und Psychotherapie. 2018;64(3):298-311.
42. Segato A, Marzullo A, Calimeri F, De Momi E. Artificial intelligence for brain diseases: A systematic review. APL bioengineering. 2020;4.(۴)
43. Huang M-H, Rust RT. Artificial intelligence in service. Journal of service research. 2018;21(2):155-72.
44. Hamet P, Tremblay J. Artificial intelligence in medicine. Metabolism. 2017;69:S36-S40.
45. Lu H, Li Y, Chen M, Kim H, Serikawa S. Brain intelligence: go beyond artificial intelligence. Mobile Networks and Applications. 2018;23:368-75.
46. Jiang F, Jiang Y, Zhi H, Dong Y, Li H, Ma S, et al. Artificial intelligence in healthcare: past, present and future. Stroke and vascular neurology. 2017;2(4).
47. ATANASOVA A, MARINOVA N, ILIEV K. INTERACTION BETWEEN TYPES OF
48. ARTIFICIAL INTELLIGENCE. Scientific Research & Education in the Air Force-AFASES. 2022;2022.
49. Graham S, Depp C, Lee EE, Nebeker C, Tu X, Kim H-C, et al. Artificial intelligence for mental health and mental illnesses: an overview. Current psychiatry reports. 2019;21:1-18.
50. Balbuena J, Samamé H, Almeyda S, Mendoza J, Pow-Sang JA, editors. Depression detection using audio-visual data and artificial intelligence: A systematic mapping study. Proceedings of Fifth International Congress on Information and Communication Technology:

ICICT 2020, London, Volume 2; 2021: Springer.
51. Popescu C, Golden G, Benrimoh D, Tanguay-Sela M, Slowey D, Lundrigan E, et al. Correction: Evaluating the Clinical Feasibility of an Artificial Intelligence–Powered, Web-Based Clinical Decision Support System for the Treatment of Depression in Adults: Longitudinal Feasibility Study. JMIR Formative Research. 2024;8:e56570.
52. Benrimoh D, Tanguay-Sela M, Perlman K, Israel S, Mehltretter J, Armstrong C, et al. Using a simulation centre to evaluate preliminary acceptability and impact of an artificial intelligence-powered clinical decision support system for depression treatment on the physician– patient interaction. BJPsych open. 2021;7(1):e22.
53. Tanguay-Sela M, Benrimoh D, Popescu C, Perez T, Rollins C, Snook E, et al. Evaluating the perceived utility of an artificial intelligence-powered clinical decision support system for depression treatment using a simulation center. Psychiatry Research. 2022;308:114336.
54. Servan-Schreiber D. Artificial intelligence and psychiatry. The Journal of nervous and mental disease. 1986;174(4):191-202.
55. Rocheteau E. On the role of artificial intelligence in psychiatry. The British Journal of Psychiatry. 2023;222(2):54-7.
56. Perlman K, Benrimoh D, Israel S, Rollins C, Brown E, Tunteng J-F, et al. A systematic meta-review of predictors of antidepressant treatment outcome in major depressive disorder. Journal of Affective Disorders. 2019;243:503-15.
57. Shah RV, Grennan G, Zafar-Khan M, Alim F, Dey S, Ramanathan D, et al. Personalized machine learning of depressed mood using wearables. Translational psychiatry. 2021;11(1):1-18.
58. Lin S, Wu Y, He L, Fang Y. Prediction of depressive symptoms onset and long-term trajectories in home-based older adults using machine learning techniques. Aging & Mental Health. 2023;27(1):8-17.
59. Patel MJ, Andreescu C, Price JC, Edelman KL, Reynolds III CF, Aizenstein HJ. Machine learning approaches for integrating clinical and imaging features in late-life depression classification and response prediction. International journal of geriatric psychiatry. 2015;30(10):1056-67.
60. Li N, Feng L, Hu J, Jiang L, Wang J, Han J, et al. Using deep time-series semantics to assess depressive symptoms based on clinical interview speech. Frontiers in Psychiatry. 2023;14:1104190.
61. Iniesta R, Stahl D, McGuffin P. Machine learning, statistical learning and the future of biological research in psychiatry. Psychological medicine. 2016;46(12):2455-65.
62. Duda M, Ma R, Haber N, Wall D. Use of machine learning for behavioral distinction of autism and ADHD. Translational psychiatry. 2016;6(2):e732-e.
63. Luxton DD. Artificial intelligence in psychological practice: Current and future applications and implications. Professional Psychology: Research and Practice. 2014;45(5):332.
64. Vijaya KS, Chandana BH, Sugumar D, Muralidharan J, Krishna IM. Automated Seizure Detection Using Machine Learning Algorithm in Very Large Scale Integration. International Journal of Intelligent Systems and Applications in Engineering. 2024;12(7s):01-
65. Dinga et al.Irshad S, Azmi S, Begum N. Uses of Artificial Intelligence in Psychology.

Psychology. 2022;5(4):21-30.
66. Gado S, Kempen R, Lingelbach K, Bipp T. Artificial intelligence in psychology: How can we enable psychology students to accept and use artificial intelligence? Psychology Learning & Teaching. 2022;21(1):37-56.
67. Esteva A, Kuprel B, Novoa RA, Ko J, Swetter SM, Blau HM, et al. Dermatologist-level classification of skin cancer with deep neural networks. Nature. 2017;542(7639):115-8.
68. Gulshan V, Peng L, Coram M, Stumpe MC, Wu D, Narayanaswamy A, et al. Development and validation of a deep learning algorithm for detection of diabetic retinopathy in retinal fundus photographs. Jama. 2016;316(22):2402-10.
69. Wojtara M, Rana E, Rahman T, Khanna P, Singh H. Artificial intelligence in rare disease diagnosis and treatment. Clinical and Translational Science. 2023;16(11):2106-11.
70. Bharatbhai PH, Prajapati AP, Narkhede S, Luhar S. A REVIEW ON ROLE OF ARTIFICIAL INTELLIGENCE: IN DIAGNOSIS OF DISEASE AND DRUG
71. MANAGEMENT. EPRA International Journal of Research and Development (IJRD). 2023;8(12):278-83.
72. Kister K, Laskowski J, Makarewicz A, Tarkowski J. Application of artificial intelligence tools in diagnosis and treatment of mental disorders. Curr Probl Psychiatry. 2023;24:1-18.
73. Vaishnavi S. Artificial Intelligence Approach for Disease Diagnosis and Treatment. International Journal of Innovative Research in Computer and Communication Engineering. 2014;2.
74. Imperatori C, Farina B, Valenti EM, Di Poce A, D'Ari S, De Rossi E, et al. Is resting state frontal alpha connectivity asymmetry a useful index to assess depressive symptoms? A preliminary investigation in a sample of university students. Journal of Affective Disorders. 2019;257:152-9.
75. Ben-Zeev D, Scherer EA, Wang R, Xie H, Campbell AT. Next-generation psychiatric assessment: Using smartphone sensors to monitor behavior and mental health. Psychiatric rehabilitation journal. 2015;38(3):218.
76. Saeb S, Zhang M, Karr CJ, Schueller SM, Corden ME, Kording KP, et al. Mobile phone sensor correlates of depressive symptom severity in daily-life behavior: an exploratory study. Journal of medical Internet research. 2015;17(7):e4273.
77. Ding J, Hu M, editors. Research on the application of artificial intelligence in the field of depression. Proceedings of the 2nd International Symposium on Artificial Intelligence for Medicine Sciences; 2021.
78. Di Felice M, Chatterjee P, Cattaneo MFP, editors. Depression Diagnosis using Text-based AI Methods Systematic Review. ICAI Workshops; 2022.
79. Tan JCY, Rollins CPE, Israel S, Benrimoh DA. Primed for Psychiatry: The role of artificial intelligence and machine learning in the optimization of depression treatment. University of Toronto Medical Journal. 2019;96.
80. Tan J, Rollins CR, Israel S, Benrimoh D. Primed for Psychiatry: The role of artificial intelligence and machine learning in the optimization of depression treatment. University of Toronto Medical Journal. 2019;96.(١)
81. Sheikh S, Shaban K, editors. Finding behavioural and imaging biomarkers of major depressive disorder (MDD) using artificial intelligence: a review. 2020 IEEE International

Conference on Informatics, IoT, and Enabling Technologies (ICIoT); 2020: IEEE.
82. Abd-Alrazaq A, AlSaad R, Aziz S, Ahmed A, Denecke K, Househ M, et al. Wearable artificial intelligence for anxiety and depression: scoping review. Journal of Medical Internet Research. 2023;25:e42672.
83. Fulmer R, Joerin A, Gentile B, Lakerink L, Rauws M. Using psychological artificial intelligence (Tess) to relieve symptoms of depression and anxiety: randomized controlled trial. JMIR Mental Health. 2018;5(4):e9782.
84. Mehta A, Niles AN, Vargas JH, Marafon T, Couto DD, Gross JJ. Acceptability and effectiveness of artificial intelligence therapy for anxiety and depression (Youper): Longitudinal observational study. Journal of medical Internet research. 2021;23(6):e26771.
85. Sadeh-Sharvit S, Camp TD, Horton SE, Hefner JD, Berry JM, Grossman E, et al. Effects of an artificial intelligence platform for behavioral interventions on depression and anxiety symptoms: randomized clinical trial. Journal of Medical Internet Research. 2023;25:e4